Whitney Cypes, the company’s Chief Innovation Officer, noted that the regulatory approval bolsters their competitive standing in a rapidly expanding aesthetic market. Recent industry data shows consumer spending on microneedling procedures across U.S. practices climbed 33% in 2025.
In section Market Quotes
SkinHealth Systems Gains FDA Clearance for Microneedling Device
A 39% surge in SkinHealth Systems stock followed the company’s announcement that federal regulators have cleared its SkinStylus microneedling device. The jump to $1.05 per share offers a brief recovery for the aesthetics firm, which has faced a 26% decline in market value since the beginning of the year.
The SkinStylus device is cleared to treat periorbital wrinkles, facial acne scars, and hypertrophic scarring resulting from surgery or trauma on the abdomen. By securing this clearance, SkinHealth Systems aims to capture a larger share of the clinical aesthetics sector as demand for non-invasive skin treatments continues to grow.
Comments (0)
No comments yet. Be the first!